



Recommended Terms for Providers Discussing Biomarker and Germline Genetic Testing with Patients

WHAT

terms should I use to discuss testing with my patients?

WHY

should I use specific terms with my patients?

WHERE

can I learn more about recommended terms for communicating with my patients about testing in precision medicine?

“**Biomarker Testing**” to discuss tests that identify characteristics, targetable findings, or other tests results originating from malignant tissue or blood.

“**Genetic Testing for an Inherited Mutation**” and “**Genetic Testing for Inherited Cancer Risk**” for tests to identify germline mutations (also known as variants in the genetics community).

Patients are confused by variations in testing terms, and this limits their ability to understand the importance of testing and what to communicate with their HCP to ensure appropriate and comprehensive testing for their care.

A patient group-led multi-stakeholder analysis found that there are **at least 33 terms for biomarker and germline genetic testing** currently being used to educate cancer patients about testing.

Visit www.CommonCancerTestingTerms.org

Read the recently released White Paper on the **Need for Consistent Terms for Testing in Precision Medicine**

Learn more about the multi-stakeholder group that has already endorsed this terminology

Read the **ASCO 2020 abstract** on the recommended terms



BE PART OF A UNIFIED VOICE

ADOPT AND USE THE CONSISTENT
TESTING TERMINOLOGY WHEN
TALKING TO PATIENTS

- **Biomarker Testing**
- **Genetic Testing for an Inherited Mutation**
- **Genetic Testing for Inherited Cancer Risk**